search
Back to results

Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
Experimental nutritional formula #M979
Standard food
Sponsored by
Abbott Nutrition
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject has type 2 diabetes.
  2. Subject is over 18 years of age.
  3. Subject is a male, or a non-pregnant, non-lactating female.
  4. Subject's BMI is > 20 kg/m2 and < 40 kg/m2.
  5. Subject's HbA1c level is 6.5 - 11%.
  6. If on a chronic thyroid medication or hormone replacement therapy, subject has been on constant dosage for at least two months prior to Screening Visit.
  7. Subject's weight is stable for the past two months prior to Screening Visit.

Exclusion Criteria:

  1. Subject uses exogenous insulin, Byetta or alpha-glucosidase inhibitor for glucose control.
  2. Subject has type 1 diabetes.
  3. Subject has history of diabetic ketoacidosis.
  4. Subject has the following: current infection ; has had inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or antibiotics in the last 3 weeks prior to screening.
  5. Subject has an active malignancy.
  6. Subject has had significant cardiovascular event <6 months prior to study entry or history of congestive heart failure.
  7. Subject has end stage organ failure.
  8. Subject has history of severe gastroparesis, renal or hepatic disease.
  9. Subject has an active metabolic, hepatic, or gastrointestinal disease or condition that may interfere with nutrient absorption, distribution, metabolism, or excretion, excluding diabetes.
  10. Subject has a chronic, contagious, infectious disease.
  11. Taking daily medications at doses that would interfere with nutrient absorption, metabolism, excretion, gastric motility, or blood glucose.
  12. Subject has fainted or experienced other adverse event in response to blood collection prior to enrollment into this study.
  13. Clotting or bleeding disorders.
  14. Allergic or intolerant to any ingredient found in the test meal.

Sites / Locations

  • Kuban State Medical University
  • City Clinical Hospital #68
  • City Clinical Hospital #52
  • City Hospital #67
  • Novosibirsk State Medical University
  • State Novosibirsk Regional Hospital
  • Diabetes Centre, LLC
  • Medical Centre Twenty First Century
  • City Clinical Hospital #3
  • Tyumen State Medical Academy
  • Bashkir State Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Nutritional Formula #M979

Regular standard meal

Arm Description

nutritional formula

standard meal

Outcomes

Primary Outcome Measures

The primary variable is glucose concentration

Secondary Outcome Measures

Additional measures of glucose concentration

Full Information

First Posted
August 24, 2010
Last Updated
August 24, 2010
Sponsor
Abbott Nutrition
search

1. Study Identification

Unique Protocol Identification Number
NCT01188200
Brief Title
Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes
Official Title
Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
December 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Abbott Nutrition

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to demonstrate the efficacy of a nutritional formula in patients with type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
168 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nutritional Formula #M979
Arm Type
Experimental
Arm Description
nutritional formula
Arm Title
Regular standard meal
Arm Type
Active Comparator
Arm Description
standard meal
Intervention Type
Other
Intervention Name(s)
Experimental nutritional formula #M979
Intervention Description
One two hundred and forty mL serving at test time, taken orally
Intervention Type
Other
Intervention Name(s)
Standard food
Intervention Description
Standard meal prior to test time
Primary Outcome Measure Information:
Title
The primary variable is glucose concentration
Time Frame
0 to 240 minutes
Secondary Outcome Measure Information:
Title
Additional measures of glucose concentration
Time Frame
0 to 240 mins

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has type 2 diabetes. Subject is over 18 years of age. Subject is a male, or a non-pregnant, non-lactating female. Subject's BMI is > 20 kg/m2 and < 40 kg/m2. Subject's HbA1c level is 6.5 - 11%. If on a chronic thyroid medication or hormone replacement therapy, subject has been on constant dosage for at least two months prior to Screening Visit. Subject's weight is stable for the past two months prior to Screening Visit. Exclusion Criteria: Subject uses exogenous insulin, Byetta or alpha-glucosidase inhibitor for glucose control. Subject has type 1 diabetes. Subject has history of diabetic ketoacidosis. Subject has the following: current infection ; has had inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or antibiotics in the last 3 weeks prior to screening. Subject has an active malignancy. Subject has had significant cardiovascular event <6 months prior to study entry or history of congestive heart failure. Subject has end stage organ failure. Subject has history of severe gastroparesis, renal or hepatic disease. Subject has an active metabolic, hepatic, or gastrointestinal disease or condition that may interfere with nutrient absorption, distribution, metabolism, or excretion, excluding diabetes. Subject has a chronic, contagious, infectious disease. Taking daily medications at doses that would interfere with nutrient absorption, metabolism, excretion, gastric motility, or blood glucose. Subject has fainted or experienced other adverse event in response to blood collection prior to enrollment into this study. Clotting or bleeding disorders. Allergic or intolerant to any ingredient found in the test meal.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Voss, PhD
Organizational Affiliation
Abbott Nutrition
Official's Role
Study Chair
Facility Information:
Facility Name
Kuban State Medical University
City
Krasnodar
ZIP/Postal Code
350043
Country
Russian Federation
Facility Name
City Clinical Hospital #68
City
Moscow
ZIP/Postal Code
109263
Country
Russian Federation
Facility Name
City Clinical Hospital #52
City
Moscow
ZIP/Postal Code
123182
Country
Russian Federation
Facility Name
City Hospital #67
City
Moscow
ZIP/Postal Code
123423
Country
Russian Federation
Facility Name
Novosibirsk State Medical University
City
Novosibirsk
ZIP/Postal Code
630047
Country
Russian Federation
Facility Name
State Novosibirsk Regional Hospital
City
Novosibirsk
ZIP/Postal Code
630087
Country
Russian Federation
Facility Name
Diabetes Centre, LLC
City
Samara
ZIP/Postal Code
443046
Country
Russian Federation
Facility Name
Medical Centre Twenty First Century
City
St. Petersburgh
ZIP/Postal Code
190068
Country
Russian Federation
Facility Name
City Clinical Hospital #3
City
St. Petersburg
ZIP/Postal Code
195257
Country
Russian Federation
Facility Name
Tyumen State Medical Academy
City
Tyumen
ZIP/Postal Code
625023
Country
Russian Federation
Facility Name
Bashkir State Medical University
City
Ufa
ZIP/Postal Code
450071
Country
Russian Federation

12. IPD Sharing Statement

Learn more about this trial

Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes

We'll reach out to this number within 24 hrs